Combination achieved mOS of 23.8 months in patients with unresectable or metastatic HCC; FORT LEE, N.J., Oct. 14, 2026 (GLOBE ...
Combination achieved mOS of 23.8 months in patients with unresectable or metastatic HCCFORT LEE, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Elevar ...
1d
Alex Mealer holds single-digit lead over Leticia Gutierrez in Congressional District 9, poll shows
Alex Mealer is running a tighter race than many expected when Texas Republicans redrew the 9th Congressional District to ...
Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline in CST ...
Just weeks after the FDA approved an all-oral regimen for newly diagnosed acute myeloid leukemia (AML), a panel of leukemia ...
A German phase II trial called TRITICC-2 is testing whether oral trifluridine/tipiracil combined with nanoliposomal ...
On October 5, the Supreme Court held oral argument in Suncor Energy (U.S.A.) Inc. v. County Commissioners of Boulder County. The case asks whether local governments may use state tort law to hold ...
More than eight in 10 Health Savings Account and Flexible Spending Account holders would use those funds to purchase everyday ...
Question 9 asks voters whether to keep or scrap a 2024 gun law. The question is before voters because of an effort by gun ...
ViiV said the data support Cabenuva’s use in patients with detectable HIV and no resistance to INSTIs or NNRTIs.
In this study, researchers examined approval and fill rates of specialty prescriptions for blood cancers among Medicare and commercially insured patients.
ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with vire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results